Cargando…

Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4)

INTRODUCTION: The FreeStyle Libre is a flash glucose monitoring (FSL-FGM) system. Compared with finger-prick based self-monitoring of blood glucose, FSL-FGM may provide benefits in terms of improved glycemic control and decreased disease burden. METHODS: Prospective nationwide registry. Participants...

Descripción completa

Detalles Bibliográficos
Autores principales: Fokkert, Marion, van Dijk, Peter, Edens, Mireille, Barents, Eglantine, Mollema, Jeanine, Slingerland, Robbert, Gans, Reinold, Bilo, Henk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904165/
https://www.ncbi.nlm.nih.gov/pubmed/31875133
http://dx.doi.org/10.1136/bmjdrc-2019-000809
_version_ 1783477963603312640
author Fokkert, Marion
van Dijk, Peter
Edens, Mireille
Barents, Eglantine
Mollema, Jeanine
Slingerland, Robbert
Gans, Reinold
Bilo, Henk
author_facet Fokkert, Marion
van Dijk, Peter
Edens, Mireille
Barents, Eglantine
Mollema, Jeanine
Slingerland, Robbert
Gans, Reinold
Bilo, Henk
author_sort Fokkert, Marion
collection PubMed
description INTRODUCTION: The FreeStyle Libre is a flash glucose monitoring (FSL-FGM) system. Compared with finger-prick based self-monitoring of blood glucose, FSL-FGM may provide benefits in terms of improved glycemic control and decreased disease burden. METHODS: Prospective nationwide registry. Participants with diabetes mellitus (DM) used the FSL-FGM system for a period of 12 months. End points included changes in HbA1c, hypoglycemia, health-related quality of life (12-Item Short Form Health Survey(v2) (SF-12(v2)) and 3-level version of EuroQol 5D (EQ-5D-3L)), a specifically developed patient-reported outcome measures (PROMs) questionnaire, diabetes-related hospital admission rate and work absenteeism. Measurements were performed at baseline, and after 6 months and 12 months. RESULTS: 1365 persons (55% male) were included. Mean age was 46 (16) years, 77% of participants had type 1 DM, 16% type 2 DM and 7% other forms. HbA1c decreased from 64 (95%CI 63 to 65) mmol/mol to 60 (95%CI 60 to 61) mmol/mol with a difference of −4 (95% CI −6 to 3) mmol/mol. Persons with a baseline HbA1c >70 mmol/mol had the most profound HbA1c decrease: −9 (95% CI −12 to to 5) mmol/mol. EQ-5D tariff (0.03 (95%CI 0.01 to 0.05)), EQ-VAS (4.4 (95%CI 2.1 to 6.7)) and SF-12(v2) mental component score (3.3 (95%CI 2.1 to 4.4)) improved. For most, PROMs improved. Work absenteeism rate (/6 months) and diabetes-related hospital admission rate (/year) decreased significantly, from 18.5% to 7.7% and 13.7% to 2.3%, respectively. CONCLUSIONS: Real world data demonstrate that use of FSL-FGM results in improved well-being and decreased disease burden, as well as improvement of glycemic control.
format Online
Article
Text
id pubmed-6904165
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-69041652019-12-24 Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4) Fokkert, Marion van Dijk, Peter Edens, Mireille Barents, Eglantine Mollema, Jeanine Slingerland, Robbert Gans, Reinold Bilo, Henk BMJ Open Diabetes Res Care Emerging Technologies, Pharmacology and Therapeutics INTRODUCTION: The FreeStyle Libre is a flash glucose monitoring (FSL-FGM) system. Compared with finger-prick based self-monitoring of blood glucose, FSL-FGM may provide benefits in terms of improved glycemic control and decreased disease burden. METHODS: Prospective nationwide registry. Participants with diabetes mellitus (DM) used the FSL-FGM system for a period of 12 months. End points included changes in HbA1c, hypoglycemia, health-related quality of life (12-Item Short Form Health Survey(v2) (SF-12(v2)) and 3-level version of EuroQol 5D (EQ-5D-3L)), a specifically developed patient-reported outcome measures (PROMs) questionnaire, diabetes-related hospital admission rate and work absenteeism. Measurements were performed at baseline, and after 6 months and 12 months. RESULTS: 1365 persons (55% male) were included. Mean age was 46 (16) years, 77% of participants had type 1 DM, 16% type 2 DM and 7% other forms. HbA1c decreased from 64 (95%CI 63 to 65) mmol/mol to 60 (95%CI 60 to 61) mmol/mol with a difference of −4 (95% CI −6 to 3) mmol/mol. Persons with a baseline HbA1c >70 mmol/mol had the most profound HbA1c decrease: −9 (95% CI −12 to to 5) mmol/mol. EQ-5D tariff (0.03 (95%CI 0.01 to 0.05)), EQ-VAS (4.4 (95%CI 2.1 to 6.7)) and SF-12(v2) mental component score (3.3 (95%CI 2.1 to 4.4)) improved. For most, PROMs improved. Work absenteeism rate (/6 months) and diabetes-related hospital admission rate (/year) decreased significantly, from 18.5% to 7.7% and 13.7% to 2.3%, respectively. CONCLUSIONS: Real world data demonstrate that use of FSL-FGM results in improved well-being and decreased disease burden, as well as improvement of glycemic control. BMJ Publishing Group 2019-12-09 /pmc/articles/PMC6904165/ /pubmed/31875133 http://dx.doi.org/10.1136/bmjdrc-2019-000809 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Emerging Technologies, Pharmacology and Therapeutics
Fokkert, Marion
van Dijk, Peter
Edens, Mireille
Barents, Eglantine
Mollema, Jeanine
Slingerland, Robbert
Gans, Reinold
Bilo, Henk
Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4)
title Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4)
title_full Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4)
title_fullStr Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4)
title_full_unstemmed Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4)
title_short Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4)
title_sort improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (flare-nl4)
topic Emerging Technologies, Pharmacology and Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904165/
https://www.ncbi.nlm.nih.gov/pubmed/31875133
http://dx.doi.org/10.1136/bmjdrc-2019-000809
work_keys_str_mv AT fokkertmarion improvedwellbeinganddecreaseddiseaseburdenafter1yearuseofflashglucosemonitoringflarenl4
AT vandijkpeter improvedwellbeinganddecreaseddiseaseburdenafter1yearuseofflashglucosemonitoringflarenl4
AT edensmireille improvedwellbeinganddecreaseddiseaseburdenafter1yearuseofflashglucosemonitoringflarenl4
AT barentseglantine improvedwellbeinganddecreaseddiseaseburdenafter1yearuseofflashglucosemonitoringflarenl4
AT mollemajeanine improvedwellbeinganddecreaseddiseaseburdenafter1yearuseofflashglucosemonitoringflarenl4
AT slingerlandrobbert improvedwellbeinganddecreaseddiseaseburdenafter1yearuseofflashglucosemonitoringflarenl4
AT gansreinold improvedwellbeinganddecreaseddiseaseburdenafter1yearuseofflashglucosemonitoringflarenl4
AT bilohenk improvedwellbeinganddecreaseddiseaseburdenafter1yearuseofflashglucosemonitoringflarenl4